* Lonza to make blinatumomab for clinical trials
* Drug has shown early results for leukemia, non-Hodgkin’s
ZURICH, Nov 25 (Reuters) - Swiss drugs industry supplier Lonza Group LONN.VX has agreed with U.S. biotechnology firm Micromet MITI.O to manufacture a drug used to treat various hematologic cancers.
Lonza said on Wednesday it would manufacture Micromet’s blinatumomab drug for clinical trials and develop the commercial scale processes and supply the drug for market if requested.
Lonza said blinatumomab had achieved the primary endpoint in a phase II trial for treatment of patients with acute lymphoblastic leukemia, and has shown success in an ongoing phase I trial for patients with non-Hodgkin’s lymphoma. (Reporting by Emma Thomasson; Editing by Dan Lalor) ((Zurich Newsroom, email@example.com, +41 58 306 7336))